MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD

IUBMB Life

Volumn 67, Issue 3, 2015, Pages 191-201

  Chai, Jie ^a   Dong, Wei ^a   Xie, Chao ^a   Wang, Lin ^b   Han, Da Li ^a   Wang, Shan ^a   Guo, Hong Liang ^a   Zhang, Zong Li ^b  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

chemoresistance; chemosensitivity; colon cancer; DPYD; fluorouracil; microRNA; miR 494

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; MICRORNA; MICRORNA 494; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC ANTIMETABOLITE; MIRN494 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME INDUCTION; ENZYME REGULATION; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE BINDING SITE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MICRORNAS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928476581     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1361     Document Type: Article

References (30)

1. Siegel, R., Naishadham, D., and, Jemal, A., (2012) Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29.
2. Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., et al.,. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241.
3. Abdalla, E. K., Bauer, T. W., Chun, Y. S., D'Angelica, M., Kooby, D. A., et al.,. (2013) Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford) 15, 119-130.
4. Reissfelder, C., Brand, K., Sobiegalla, J., Rahbari, N. N., Bork, U., et al.,. (2014) Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases. Surgery 155, 245-254.
5. Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., et al.,. (2011) Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann. Oncol. 22, 2604-2609.
6. Paldino, E., Tesori, V., Casalbore, P., Gasbarrini, A., and, Puglisi, M. A., (2014) Tumor initiating cells and chemoresistance: which is the best strategy to target colon cancer stem cells? Biomed. Res. Int. 2014, 859871.
7. Robinson, S. M., Wilson, C. H., Burt, A. D., Manas, D. M., and, White, S. A., (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann. Surg. Oncol. 19, 4287-4299.
8. Grossi, V., Peserico, A., Tezil, T., and, Simone, C., (2014) p38alpha MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J. Gastroenterol. 20, 9744-9758.
9. Shikina, A., Shinto, E., Hashiguchi, Y., Ueno, H., Naito, Y., et al.,. (2014) Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. Jpn. J. Clin. Oncol. 44, 42-48.
10. Panczyk, M., (2014) Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J. Gastroenterol. 20, 9775-9827.
11. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., et al.,. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327.
12. Xie, L., Jing, R., Qi, J., Lin, Z., and, Ju, S., (2015) Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies. Blood Rev. 33-44.
13. Garajova, I., Le Large, T. Y., Frampton, A. E., Rolfo, C., Voortman, J., et al.,. (2014) Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed. Res. Int. 2014, 678401.
14. Bartel, D. P., (2009) MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
15. He, J., Xie, G., Tong, J., Peng, Y., Huang, H., et al.,. (2014) Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. Cell Biochem. Biophys. 70, 1343-1350.
16. Findlay, V. J., Wang, C., Nogueira, L. M., Hurst, K., Quirk, D., et al.,. (2014) SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol. Cancer Ther. 13, 2713-2726.
17. Tang, H., Zhang, P., Xiang, Q., Yin, J., Yu, J., et al.,. (2014) Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells. Pharmazie 69, 287-292.
18. Yu, Y., Sarkar, F. H., and, Majumdar, A. P., (2013) Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl. Oncol. 6, 180-186.
19. Chen, C., Ridzon, D. A., Broomer, A. J., Zhou, Z., Lee, D. H., et al.,. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179.
20. Marin, J. J., Sanchez de Medina, F., Castano, B., Bujanda, L., Romero, M. R., et al.,. (2012) Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab. Rev. 44, 148-172.
21. Marino, A. L., Evangelista, A. F., Vieira, R. A., Macedo, T., Kerr, L. M., et al.,. (2014) MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study. BMC Cancer 14, 739.
22. Lim, L., Balakrishnan, A., Huskey, N., Jones, K. D., Jodari, M., et al.,. (2014) MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 59, 202-215.
23. Shen, P. F., Chen, X. Q., Liao, Y. C., Chen, N., Zhou, Q., et al.,. (2014) MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate 74, 756-767.
24. He, W., Li, Y., Chen, X., Lu, L., Tang, B., et al.,. (2014) miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J. Gastroenterol. Hepatol. 29, 1427-1434.
25. Kim, W. K., Park, M., Kim, Y. K., Tae, Y. K., Yang, H. K., et al.,. (2011) MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin. Cancer Res. 17, 7584-7594.
26. Bai, Y., Sun, Y., Peng, J., Liao, H., Gao, H., et al.,. (2014) Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494. Oncotarget 5, 7760-7775.
27. Mattison, L. K., Soong, R., and, Diasio, R. B., (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3, 485-492.
28. Ezzeldin, H., and, Diasio, R., (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin. Colorectal Cancer 4, 181-189.
29. Ciccolini, J., Mercier, C., Evrard, A., Dahan, L., Boyer, J. C., et al.,. (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit. 28, 678-685.
30. Vallbohmer, D., Yang, D. Y., Kuramochi, H., Shimizu, D., Danenberg, K. D., et al.,. (2007) DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int. J. Oncol. 31, 413-418.